Shire plc (ADR) (NASDAQ:SHPGY)

CAPS Rating: 4 out of 5

A pharmaceutical company that focuses on meeting the needs of the specialist physician.

Recs

0
Player Avatar CuriousDonkey (55.86) Submitted: 7/6/2010 3:57:40 PM : Outperform Start Price: $62.52 SHPGY Score: +13.29

As Genzyme continues to suffer with FDA and EU concerns, Shire is swooping in and displacing a captive market. This company is amping up a significant manufacturing base and jumping at the opportunity to gill Genzyme's market.

Featured Broker Partners


Advertisement